Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from LLY

The Saturday Spread: Using the Neglected Methodology That Wall Street Refuses to Teach

While understanding so-called ‘options math’ can provide interesting context and color, the real alpha generation comes from an entirely different framework.

Barchart

Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly

Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats.

MarketBeat

Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst

Eli Lilly and Co (NYSE:LLY) released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?

Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone.

MarketBeat

Eli Lilly Co. Q2 FY2025 Earnings Transcript

Eli Lilly Co. (NYSE:LLY) reported its second-quarter 2025 financial results ahead of the opening bell on Thursday.

Benzinga

Apple Jumps, Eli Lilly Crashes On Worst Day In 25 Years: What's Moving Markets Thursday?

U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove divergent moves in heavyweight names.

Benzinga

This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially making it the top choice for patients with Type 2 diabetes.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Stocks Turn Mixed After an Early Rally

The S&P 500 Index ($SPX ) (SPY ) today is down -0.04%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.53%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.44%. September E-mini S&P futures (ESU25 ) are down -0.04%, and September E-mini Nasdaq futures...

Barchart

Stocks Rally on Positive Tariff News ad Rate Cut Hopes

The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.71%. September E-mini S&P futures (ESU25 ) are up +0.53%, and September E-mini Nasdaq futures...

Barchart

Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk (UPDATED)

Eli Lilly and Co. (NYSE:LLY) stock plunged on Thursday after the company released topline data from the Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

Benzinga

RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program

Three major pharmaceutical companies — Amgen Inc. (NASDAQ:AMGN), Eli Lilly and Co (NYSE:LLY), and UCB SA (OTC:UCBJY) (OTC:UCBJF) — are suing U.S. Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. over the way his department is handling a drug discount program.

Benzinga

How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings

Eli Lilly and Company (NYSE:LLY) will release earnings results for the second quarter before the opening bell on Thursday, Aug. 7.

Benzinga

Is Wall Street Bullish or Bearish on Eli Lilly Stock?

Eli Lilly shares have underperformed the broader market over the past year, but Wall Street analysts remain firmly bullish in the company’s long-term growth prospects.

Barchart

Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity (dulaglutide), a GLP-1 receptor agonist.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What's Going On With Eli Lilly Stock On Tuesday?

Eli Lilly and Co. (NYSE:LLY) stock is trading lower on Tuesday after its weight loss drug rival, Novo Nordisk A/S (NYSE:NVO), trimmed its 2025 financial outlook.

Benzinga

Drug Prices To Get 'More Expensive' Under Trump's EU Trade Deal As Pharma Faces Billions In Added Costs: Report

The pharmaceutical industry could face a significant financial hit due to the new trade deal between the U.S. and the European Union (EU), potentially leading to increased drug prices and restricted access.

Benzinga

Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption'

Health and Human Services Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program, describing the system as fundamentally broken and failing its intended purpose.

Benzinga

Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China

In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY) Zepbound from flooding the market.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

Benzinga

Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Friday recommending Eli Lilly and Co.’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers.

Barchart

Earnings Preview: What to Expect From Eli Lilly's Report

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit growth.

Benzinga

Ozempic, Mounjaro Users Cut $6.5 Billion From Grocery Bills: GLP-1 Boom Triggers Panic In Packaged Food Aisles

GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs fundamentally altering consumer food purchasing patterns across America’s retail landscape.

Benzinga

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to “benefit” from the levies.

MarketBeat

Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season

These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025

Benzinga

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround

While multinational pharmaceutical firm Eli Lilly and Company (NYSE:LLY) represents one of the top drugmakers in the world, that status alone hasn't exempted its equity from underperformance. In the past 52 weeks, LLY stock finds itself down almost 16%. Since the beginning of this year, LLY has barely poked its…

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.